BCRX logo

BIOCRYST PHARMACEUTICALS INC

BCRXNASDAQ
πŸ† #1868 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track BCRX
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$1.86B
Small Cap
πŸ“ˆRevenue Growth (YoY)
60.3%
High Growth
πŸ“ŠGross Margin
97.9%
High
πŸ’΅FCF Margin
46.1%
Strong
βš–οΈP/S Ratio
2.0x
Cheap
Otter Score
80
Strong
No chart data available for BCRX.

Trading Snapshot

Day Range
β€”
52-Week Range
$6.23 – $11.22
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
255.5M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$875M
Last Q Revenue
$180M
P/E Ratio
β€”
P/S Ratio
2.0x
EPS (TTM)
$-1.42
Dividend Yield
β€”
Dilution (1yr)
+5.7%
BCRX logo

BIOCRYST PHARMACEUTICALS INC

BCRX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$875Mβ–² +94.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
97.8%β–² +0.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$341Mβ–Ό βˆ’13508.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$327Mβ–Ό βˆ’716.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
219.3Mβ–² +5.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$349Mβ–² +$387M YoY
StockOtter Β· stockotter.space

About BIOCRYST PHARMACEUTICALS INC

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
80/100
Analyst data unavailable.

Latest News & Updates

News unavailable.